Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD334 phase 2 study in moderately to severely active ulcerative colitis
2015-001942-28Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing etrasimod with placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Sep 2015; status: completed.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-001942-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001942-28.